Alston & Bird has named partner Natalie Clayton as the head of its Biotechnology, Pharmaceutical & Life Sciences Patent Litigation Team, effective immediately.
“Natalie has been a leader in our IP group for many years and has played a central role in its development and growth,” said Keith Broyles, Alston & Bird partner and co-chair of the firm’s Intellectual Property Practice. “Our clients are among the most innovative biotech, pharma, and life sciences companies in the world, and I can’t think of a better choice than Natalie to lead our team in advising them on asset protection strategies to secure and defend market exclusivity and create greater opportunities for return on investment.”
Clayton has more than 10 years of experience guiding industry-leading companies through sophisticated patent litigation, as well as complex Food and Drug Administration regulatory matters. Her practice is grounded in a keen understanding of her clients' business goals, as well as in-depth knowledge of how to litigate a case to trial, and win. She has represented clients in trials throughout the United States and has particular mastery in Hatch-Waxman cases. She has also been involved in patent cases covering diverse areas of technology, including pharmaceuticals, software, chemical, and medical and mechanical devices.
Recognized by the marketplace as a leader in patent law, Clayton has been named to the Intellectual Asset Management (IAM) Patent 1000 – The World’s Leading Patent Professionals for the past four consecutive years and was highlighted by the publication in 2017 as a “rising star with plenty on her plate.”
Clayton also served on the editorial committee overseeing the writing of the USPTO Post-Grant Trials Handbook, a book for navigating post-grant proceedings of the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) that was edited by Alston & Bird partners Ben Pleune and Christopher Douglas and published by Wolters Kluwer.
Known for its outstanding reputation representing both plaintiffs and defendants in high-profile, high-stakes patent litigation, Alston & Bird’s Biotechnology, Pharmaceutical & Life Sciences Patent Litigation Team comprises approximately 20 patent litigators and has litigated pharmaceutical and biotechnology matters for nearly two decades. While focusing on the industry heavyweight districts of New Jersey and Delaware, the group has also represented clients in federal court in West Virginia, Florida, Northern California, and Maryland, among others. Additionally, the team has built a robust practice in strategically challenging patents before the PTAB in inter partes review proceedings, working hand-in-hand with clients to achieve leverage in reaching ultimate, and successful, dispute resolution.
“Natalie has been a leader in our IP group for many years and has played a central role in its development and growth,” said Keith Broyles, Alston & Bird partner and co-chair of the firm’s Intellectual Property Practice. “Our clients are among the most innovative biotech, pharma, and life sciences companies in the world, and I can’t think of a better choice than Natalie to lead our team in advising them on asset protection strategies to secure and defend market exclusivity and create greater opportunities for return on investment.”
Clayton has more than 10 years of experience guiding industry-leading companies through sophisticated patent litigation, as well as complex Food and Drug Administration regulatory matters. Her practice is grounded in a keen understanding of her clients' business goals, as well as in-depth knowledge of how to litigate a case to trial, and win. She has represented clients in trials throughout the United States and has particular mastery in Hatch-Waxman cases. She has also been involved in patent cases covering diverse areas of technology, including pharmaceuticals, software, chemical, and medical and mechanical devices.
Recognized by the marketplace as a leader in patent law, Clayton has been named to the Intellectual Asset Management (IAM) Patent 1000 – The World’s Leading Patent Professionals for the past four consecutive years and was highlighted by the publication in 2017 as a “rising star with plenty on her plate.”
Clayton also served on the editorial committee overseeing the writing of the USPTO Post-Grant Trials Handbook, a book for navigating post-grant proceedings of the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) that was edited by Alston & Bird partners Ben Pleune and Christopher Douglas and published by Wolters Kluwer.
Known for its outstanding reputation representing both plaintiffs and defendants in high-profile, high-stakes patent litigation, Alston & Bird’s Biotechnology, Pharmaceutical & Life Sciences Patent Litigation Team comprises approximately 20 patent litigators and has litigated pharmaceutical and biotechnology matters for nearly two decades. While focusing on the industry heavyweight districts of New Jersey and Delaware, the group has also represented clients in federal court in West Virginia, Florida, Northern California, and Maryland, among others. Additionally, the team has built a robust practice in strategically challenging patents before the PTAB in inter partes review proceedings, working hand-in-hand with clients to achieve leverage in reaching ultimate, and successful, dispute resolution.